215 related articles for article (PubMed ID: 27425382)
21. Pasireotide for the Medical Management of Feline Hypersomatotropism.
Scudder CJ; Gostelow R; Forcada Y; Schmid HA; Church D; Niessen SJ
J Vet Intern Med; 2015; 29(4):1074-80. PubMed ID: 25945588
[TBL] [Abstract][Full Text] [Related]
22. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.
Slingerland LI; Voorhout G; Rijnberk A; Kooistra HS
Domest Anim Endocrinol; 2008 Nov; 35(4):352-61. PubMed ID: 18801640
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of diabetes mellitus in five cats with somatotrophic abnormalities.
Norman EJ; Mooney CT
J Feline Med Surg; 2000 Dec; 2(4):183-90. PubMed ID: 11716617
[TBL] [Abstract][Full Text] [Related]
25. Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.
Scudder CJ; Hazuchova K; Gostelow R; Church DB; Forcada Y; Fowkes RC; Niessen SJ
J Feline Med Surg; 2021 Feb; 23(2):131-137. PubMed ID: 32684121
[TBL] [Abstract][Full Text] [Related]
26. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
Sartorio A; Arosio M; Conti A; Ferrero S; Porretti S; Faglia G
J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
[TBL] [Abstract][Full Text] [Related]
27. Exogenous insulin treatment after hypofractionated radiotherapy in cats with diabetes mellitus and acromegaly.
Dunning MD; Lowrie CS; Bexfield NH; Dobson JM; Herrtage ME
J Vet Intern Med; 2009; 23(2):243-9. PubMed ID: 19192146
[TBL] [Abstract][Full Text] [Related]
28. Analytical, physiologic, and clinical validation of a radioimmunoassay for measurement of procollagen type III amino terminal propeptide in serum and bronchoalveolar lavage fluid obtained from dogs.
Schuller S; Valentin S; Remy B; Jespers P; Foulon S; Van Israël N; Clercx C; McEntee K
Am J Vet Res; 2006 May; 67(5):749-55. PubMed ID: 16649905
[TBL] [Abstract][Full Text] [Related]
29. Feline acromegaly: an underdiagnosed endocrinopathy?
Niessen SJ; Petrie G; Gaudiano F; Khalid M; Smyth JB; Mahoney P; Church DB
J Vet Intern Med; 2007; 21(5):899-905. PubMed ID: 17939541
[TBL] [Abstract][Full Text] [Related]
30. Propeptide levels of procollagen type IV (NC1) and III (PIIINP) in patients undergoing haemodialysis.
Keller F; Dingeldein K; Ser YL; Schuppan D
Int Urol Nephrol; 1993; 25(3):305-8. PubMed ID: 8225832
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of hypersomatotropism and hyperthyroidism in cats with diabetes mellitus from referral centers in Buenos Aires (2020-2022).
Miceli DD; García JD; Rey Amunategui JP; Pompili GA; Rial LA; Más J; Molina EM; Pignataro OP
J Feline Med Surg; 2023 Feb; 25(2):1098612X221148565. PubMed ID: 36779783
[TBL] [Abstract][Full Text] [Related]
32. Aminoterminal propeptide of type III procollagen in cord blood and amniotic fluid of high-risk pregnancies: a biochemical approach to the dynamic assessment of deviant fetal growth.
Vanhaesebrouck P; Kint J; Van Kets H; Govaert P; Smets K; Defoort P; Leroy J
Pediatr Res; 1994 Jul; 36(1 Pt 1):71-6. PubMed ID: 7936841
[TBL] [Abstract][Full Text] [Related]
33. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
34. Serum concentration of amino-terminal propeptide of type III procollagen (PIIINP) as a prognostic marker for skin fibrosis after scar correction in burned patients.
Ulrich D; Noah EM; Burchardt ER; Atkins D; Pallua N
Burns; 2002 Dec; 28(8):766-71. PubMed ID: 12464475
[TBL] [Abstract][Full Text] [Related]
35. Feline acromegaly: an essential differential diagnosis for the difficult diabetic.
Niessen SJ
J Feline Med Surg; 2010 Jan; 12(1):15-23. PubMed ID: 20123483
[TBL] [Abstract][Full Text] [Related]
36. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
Kniess A; Ziegler E; Thieme D; Müller RK
J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
[TBL] [Abstract][Full Text] [Related]
37. Different effects of thyroid disease on serum levels of procollagen III N-peptide and hyaluronic acid.
Faber J; Hørslev-Petersen K; Perrild H; Lorenzen I
J Clin Endocrinol Metab; 1990 Oct; 71(4):1016-21. PubMed ID: 2401705
[TBL] [Abstract][Full Text] [Related]
38. Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report.
Sartorio A; Agosti F; Marazzi N; Maffiuletti NA; Cella SG; Rigamonti AE; Guidetti L; Di Luigi L; Muller EE
Clin Endocrinol (Oxf); 2004 Oct; 61(4):487-93. PubMed ID: 15473882
[TBL] [Abstract][Full Text] [Related]
39. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology.
Jensen LT
Dan Med Bull; 1997 Feb; 44(1):70-8. PubMed ID: 9062765
[TBL] [Abstract][Full Text] [Related]
40. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment.
Meduri GU; Tolley EA; Chinn A; Stentz F; Postlethwaite A
Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1432-41. PubMed ID: 9817690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
